NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification
| Autor: | Ankit A. Desai, Wei Sun, Micheala A. Aldred, Christopher J. Rhodes, Evan L. Brittain, Stephen Y. Chan, Kathryn T. Hall, Mark W. Geraci, William M. Oldham, Andrew J. Sweatt, Jane A. Leopold, Joshua P. Fessel, Susan Dina Ghiassian, Feixiong Cheng, John Barnard, Joseph Loscalzo, Martin R. Wilkins, Neil R. Aggarwal, Rebecca Vanderpool, Lei Xiao, William C. Nichols, Anna R. Hemnes, Evelyn M. Horn, Brian D. Modena, Sara Lindström, Roham T. Zamanian, Mohit Jain, Michael H. Cho, Joe G.N. Garcia, Rachel S. Kelly, Beth Wilmot |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Lung business.industry Vascular disease 030204 cardiovascular system & hematology Precision medicine medicine.disease Omics Medical research Pulmonary hypertension Clinical trial 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure Drug development medicine 030212 general & internal medicine Cardiology and Cardiovascular Medicine Intensive care medicine business |
| Zdroj: | Journal of the American College of Cardiology. 77:2040-2052 |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/j.jacc.2021.02.056 |
| Popis: | The National Heart, Lung, and Blood Institute and the Cardiovascular Medical Research and Education Fund held a workshop on the application of pulmonary vascular disease omics data to the understanding, prevention, and treatment of pulmonary vascular disease. Experts in pulmonary vascular disease, omics, and data analytics met to identify knowledge gaps and formulate ideas for future research priorities in pulmonary vascular disease in line with National Heart, Lung, and Blood Institute Strategic Vision goals. The group identified opportunities to develop analytic approaches to multiomic datasets, to identify molecular pathways in pulmonary vascular disease pathobiology, and to link novel phenotypes to meaningful clinical outcomes. The committee suggested support for interdisciplinary research teams to develop and validate analytic methods, a national effort to coordinate biosamples and data, a consortium of preclinical investigators to expedite target evaluation and drug development, longitudinal assessment of molecular biomarkers in clinical trials, and a task force to develop a master clinical trials protocol for pulmonary vascular disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|